"25x-NBOMe" type molecules - Available information on the diffusion of a class of NPS in France

 

epfammx6.jpg

Memo, OFDT, 25 p.
June 2017

Within the vast category of new psychoactive substances, 25x-NBOMe or NBOMe represents a group of compounds in the phenethylamine family, which mainly has a hallucinogenic and psychedelic effect in particular.

These compounds, which are sometimes sold and used instead of LSD, have emerged on the French market over the past five years.

Based on the different activities carried out by the TREND-SINTES schemes and the I-TREND European project, this summary attempts to explain how 25x-NBOMe were able to attract obvious interest among certain users. It describes the way in which these substances have established a presence in France, according to a relatively symbolic diffusion pattern for new hallucinogenic substances. This analysis also focuses on the prospects for changes and the limits of their presence on French territory. Lastly, it presents and describes their inherent challenges and problems, particularly in relation to health.


Authors : Magali Martinez, Agnès Cadet-Taïrou,Thomas Néfau with the TREND network coordinators

Download the PDF file (518 Ko)

 

 

 

 

 

 

 

 

Drugs in Europe


2021 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.